Labex IGO - LATEST NEWS

Shifting from treating symptoms to curing diseases and making Europe the world leader in Advanced Therapies is the aspiration of RESTORE – the Large-Scale Research Initiative, led by Charité and Berlin Institute of Health (BIH). On Febr. 09, 2019, the European Commission (EC) backed that vision and announced that RESTORE will receive initial funding of EUR 1 Million, and invited the consortium to develop fully their concept and to expand further the community that strives to propel Europe to the forefront in Advanced Therapies. For more information, please download the press release.

This MOOC, proposed by LabEx IRON, presents stakes of the use of radioactivity in Health.
After a brief introduction on the physical basis of radioactivity, the MOOC "at the heart of medical radioactivity" will present in different stages the interest of medical radioactivity, from the design of a radiopharmaceutical to its use in the patient. The public objective of this MOOC is to demonstrate the medical use of radioactivity and its modalities.
Beginning of classes on February 25, 2019.
To register to the MOOC

The overall concept of the COD1 workshop is to explore existing and publicly available omics (i.e. transcriptomic) data, facilitated by the usage of the Gene Expression Browser (GXB), to highlight knowledge gaps and potential novel discoveries. The concept of COD2 is to assemble a list of datasets (aka Series or GSE), publicly available for download from the Gene Expression Omnibus (GEO) website, relevant to a specific subject matter and to present the collection via the Gene Expression Browser (GXB). GXB is a user-friendly, open-source, and interactive web application that allows the query, visualization, and comparison of gene expression data. The workshop is composed of presentations, demonstrations and hands on activities. Post-workshop voluntary hands-on activities (i.e. "homework”) will be assigned during or shortly after the workshop. All post-workshop work will be coordinated via a web application and/or via in person Q&A session upon request. The endpoint is a short manuscript, with possibility of co-authorship credits for the volunteers. Registration is free but mandatory. Programme to download here.
This workshop is organized by Sophie Brouard and Dr. Mathieu Garand, department of Systems Biology and Immunology, Sidra Medical and Research Center, Doha

Webinar sponsorisé par Qiagen sur le séquençage de TCR (Nathalie Labarrière)
Webinar N. Labarrière

The next SAB meeeting took place on April 19th & 20th, 2018 in Nantes. You can download his report here.

"Multiplex CRISPR/Cas9 system imparis HCMV replication by excising an essential viral gene" PlosONE. This work was supported by the Labex IGO project.

Video O Tablo 1
Video O Tablo 2

Glatiramer Acetate Stimulates Regulatory B Cell Functions

Amrouche K, Pers JO, Jamin C

J Immunol. 2019 Feb 11 - Download full text

The regulatory capacity of B cells directs the aggressiveness of CLL

Mohr A, Cumin M, Bagacean C, Pochard P, Le Dantec C, Hillion S, Renaudineau Y, Berthou C, Tempescul A, Saad H, Pers JO, Bordron A, Jamin C

Oncoimmunology. 2018 Dec 12;8(3):1554968

CD9+ Regulatory B Cells Induce T Cell Apoptosis via IL-10 and Are Reduced in Severe Asthmatic Patients

Brosseau C, Durand M, Colas L, Durand E, Foureau A, Cheminant MA, Bouchaud G, Castan L, Klein M, Magnan A, Brouard S

Front Immunol. 2018 Dec 21;9:3034 - Download full text

TCR Analyses of Two Vast and Shared Melanoma Antigen-Specific T Cell Repertoires: Common and Specific Features

Simon S, Wu Z, Cruard J, Vignard V, Fortun A, Khammari A, Dreno B, Lang F, Rulli SJ, Labarriere N

Front Immunol. 2018 Aug 30;9:1962 - Download full text

IL-21 Increases the Reactivity of Allogeneic Human Vγ9Vδ2 T Cells Against Primary Glioblastoma Tumors

Joalland N, Chauvin C, Oliver L, Vallette FM, Pecqueur C, Jarry U, Scotet E

J Immunother. 2018 Jun;41(5):224-231

Paul Pascale

Evaluation de l'alloactivité humorale des cellules Natural Killer chez les patients transplantés d'organe

Centre de recherche en cardiovasculaire et nutrition, C2VN, INSERM 1263, Aix Marseille Université
27 février, 2019, 14h30 - Amphi. D. Escande

Mélanome : les promesses de l’immunothérapie

Booster le système immunitaire des patients pour les aider à lutter eux-mêmes contre leur cancer ! Telle est la mission de l'immunothérapie. Travaillant depuis 25 ans sur le sujet et notamment sur le mélanome, une équipe de recherche du Centre Régional de Recherche en Cancérologie Nantes-Angers (CRCNA) étudie les spécificités et les fonctions d'un nouveau type de lymphocytes T, appelés lymphocytes T double-positifs, qu'elle a découvert en 2009 dans des mélanomes de stade avancé. Ces lymphocytes T sont-ils des alliés contre cette tumeur ? Comment l'équipe procède-t-elle pour le savoir ? Suivez pas à pas leurs recherches et leurs premiers résultats. Ce film a été réalisé grâce au soutien de la Région Pays de la Loire sur le projet "Impact des lymphocytes T αβ double positifs CD4+CD8+ intra-tumoraux sur la réponse immune anti-mélanome »